Vertellus Acquires CENTAURI Technologies and Rebrands as Aurorium

14 Mar 2023
www.coatingsworld.com
Acquisition
Aurorium, formerly Vertellus, announced the acquisition of CENTAURI Technologies. The addition of CENTAURI’s complementary specialty material product portfolio and advanced manufacturing capabilities expands Aurorium’s offering and extends its reach in high-growth end markets. In addition to the acquisition, the company announced that it has changed its official name from Vertellus to Aurorium. Aurorium’s brand identity better represents the company’s growth and evolution as a global materials innovation partner with a diversified portfolio of specialty ingredients and performance-enhancing materials. CENTAURI is a technology driven manufacturer of specialty materials, serving a global customer base in high-growth personal care, coatings, and transportation markets from its state-of-the-art production facility in Pasadena, TX. CENTAURI’s specific expertise in hydroformylation and hydrogenation processes, including high pressure, high melt, and other complex capabilities, is highly complementary to Aurorium’s strategy and strengthens its position as a provider of specialty ingredients and performance-enhancing materials. CENTAURI is the sixth acquisition Aurorium has completed since 2019, following Bercen Chemicals, Chemtrade Life Sciences, IM Chemical, Jarchem Innovative Ingredients, and Polyscope Polymers. “CENTAURI is an exciting addition to Aurorium as we continue to expand our presence in specialty ingredients and materials,” said John Van Hulle, Aurorium CEO. “CENTAURI adds a complementary portfolio of high-quality solutions, differentiated manufacturing capabilities, and an impressive track record of innovation and growth. With CENTAURI’s customer-focused approach and exceptional engineering capabilities joining our platform, Aurorium is well-positioned to capitalize on growth across our end markets.” “Our new name and identity, Aurorium, better represents the strength of our platform and growth opportunity for our business,” said Faye Freeman, president of Aurorium. “As Aurorium, we are well-positioned to expand our products and markets, and more effectively serve our customers with a wide range of solutions that are essential to their businesses. Aurorium is committed to delivering a best-in-class customer experience, innovative solutions, and dynamic partnerships to help our customers thrive in an increasingly competitive global marketplace.” Aurorium is owned by Pritzker Private Capital and management.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.